At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Priming Immunotherapy in Advanced Disease With Radiation
In Brief
A Phase 2 clinical trial evaluating Immune checkpoint inhibitor and Radiation Therapy for Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck. Completed, enrolled 76 participants across 1 site.
Detailed Summary
This study proposes to treat metastatic non-small cell lung cancer (NSCLC) and head/neck squamous cell cancer (HNSCC) patients who are already initiating an immune checkpoint inhibitor (such as Nivolumab, Atezolizumab or Pembrolizumab) for disease treatment as per FDA approved guidelines. In these patients we will deliver a short-course radiation to a single systemic (non-CNS) site within 14 days of receiving the first dose of immune checkpoint inhibitors. This sequence allows radiation to release tumor antigens from immune inaccessible areas such as necrotic tumor or low perfusion to provide a robust anti-tumor immune response with immune checkpoint inhibitors. The primary objective is to assess six-month progression free survival (PFS) compared to historical control.
Study Details
Timeline
Interventions
Standard of care immune checkpoint inhibitor
Stereotactic Body Radiation Therapy OR Fractionated radiation therapy